ARX.AU Aroa Biosurgery Ltd

Healthcare Metals & Mining Australian Securities Exchange
0.5500 AUD
Close of Nov 1, 2026
0.4750 0.8000
Market cap
AUD 193M
P/E
55.0x
P/B
2.33x
ROE
5.0%
Dividend yield
-
Fundamental score
2.1/5

Ratios use the latest price and the fiscal year ending Mar 2026.

Is ARX.AU undervalued?

Graham number
Price0.5500
Graham value0.2305
Premium138.6%

ARX.AU trades 138.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aroa Biosurgery Ltd fundamental analysis

10 of 22 checks passed

ROE 0/2

Low return on equity (5.0%), below 10%.

ROA 1/1

Return on assets (4.1%) is above the industry median (-16.3%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (213.8%) is above the industry median (23.6%).

Revenue Growth 2/2

Revenue grew 15.9% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (6.4%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 10.4x against interest expense, well covered.

PE vs Market 0/1

PE (55.0x) is above the market median (15.0x).

PE vs Industry 0/1

PE (55.0x) is above the industry median (9.9x).

PBV 0/1

Price to book (2.3x) is above the industry median (1.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 128.1, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Aroa Biosurgery Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aroa Biosurgery Ltd

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symp…

Full company profile